Notícias

This dark horse in the weight loss drug race is worth keeping on your watch list.

The company is riding an incredible tailwind.

Eli Lilly (NYSE:LLY) is the stock everyone wants to talk about, and the reasons are obvious: Mounjaro revenue jumped 125% to $8.66 billion last quarter, the company raised full-year revenue guidance to $82 to $85 billion, and the market cap now sits at roughly $881.8 billion. But here’s what you should actually be watching. The ... Three Biotechs That Are Top Takeover Targets

These stocks could look like steals in a few years.

The Dow Jones Industrial Average, Nasdaq Composite and S&P 500 Index were down in late-morning tradi

Baxfendy gained FDA clearance for uncontrolled hypertension patients as AstraZeneca expands its cardiovascular and metabolic portfolio.

Drugmaker sees international markets as next test for obesity pill demand.

Novo Nordisk's (NYSE:NVO) oral version of its blockbuster weight-loss drug Wegovy continues to outpace its main competitor despite a slight weekly decline in prescriptions, according to Citi's latest tracking data. The bank's weekly prescription tracker, based on IQVIA data, showed Wegovy...

As next-generation GLP-1 contenders rise, key readouts are on the way from Pfizer, Viking Therapeutics and Eli Lilly.

Recent performance snapshot for Novo Nordisk (NVO) With no single headline event driving the move, Novo Nordisk (NVO) has drawn attention after a mixed stretch for the stock, including a gain of about 10% over the past month alongside weaker longer term returns. See our latest analysis for Novo Nordisk. Recent trading paints a mixed picture, with the share price up about 10% over the past month yet down over longer horizons, including a year to date decline of 14.6% and a 1 year total...

Promising clinical trial data suggests big opportunity with Eli Lilly's retatrutide GLP-1 candidate.

There's a new challenger to the more established players in the weight-loss drug space.

Novo Nordisk has cancelled a planned US$1.33b rare disease factory project in Odense and will instead convert the site into a warehouse. The decision affects local job expectations and reflects cost cutting and capital reallocation within the company. The shift comes as Novo Nordisk pursues regulatory and clinical progress on next generation anti obesity therapies. Novo Nordisk (CPSE:NOVO B), currently trading around DKK299.2, is making this change after a period of mixed share...

Can Novo Nordisk thrive under intense competitive pressures?

European equities traded in the US as American depositary receipts were sharply lower late Friday mo

Hims & Hers faces profit pressure in first-quarter 2026, though subscribers increase and a Novo Nordisk GLP-1 partnership broadens weight-loss care.

The race to dominate the weight-loss drug market is heating up, and investors should start watching this one smaller player closely.

Novo Nordisk and Biogen are underpriced and stand to gain from new indications for their blockbuster therapies.

For a decade, owning anything outside the S&P 500 felt like paying tuition to learn a lesson you already knew. International developed equities lagged, the dollar marched higher, and every diversification pitch sounded like an apology. That trade has flipped. Over the past year, Vanguard FTSE Developed Markets ETF (NYSEARCA:VEA) returned 34% against the S&P ... International Stocks Keep Crushing the S&P. This Cheap ETF Is How You Get In

Gregory Demopulos: Thank you, Jennifer, and good afternoon, everyone. Joining me today are David Borges, our Chief Accounting Officer; Dr. Cathy Melfi, our Chief Regulatory Officer; and Dr. Steve Whitaker, Vice President of Clinical. After that, David will cover the financials in more detail and then we'll open the call for questions.

Novo Nordisk (NYSE:NVO) released new clinical trial data from higher dose and oral Wegovy, including OASIS 4 and STEP UP, presented at ECO2026. The trials report significant weight loss, improved physical function, and benefits across diverse patient groups, including older adults. Results indicate better efficacy and tolerability for oral Wegovy compared with orforglipron, reinforcing Novo Nordisk's position in obesity treatment. Novo Nordisk, known for its diabetes and obesity therapies,...

European equities traded in the US as American depositary receipts were moving higher late Thursday

Novo Nordisk (NYSE:NVO) is one of the cheap stocks to buy for the next 10 years. On May 13, Novo Nordisk presented new data from the OASIS 4 clinical trial at the European Congress on Obesity 2026, highlighting the effectiveness of the oral Wegovy pill (25 mg). The findings reveal that nearly one-third of participants […]

NVO beats Q1 estimates and raises its 2026 outlook. Meanwhile, Eli Lilly's expanding GLP-1 portfolio threatens its obesity market dominance.

Pfizer stock slipped after Q1 results despite an earnings beat as investors weighed falling COVID sales and looming patent expirations.

Moby summary of Omeros Corporation's Q1 2026 earnings call

Omeros (NASDAQ:OMER) reported first-quarter 2026 net income of $56.1 million, or $0.78 per share, as the company began commercial sales of YARTEMLEA, its recently approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA. Chairman and Chief Executive

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 15 years by 17.52% on an annualized basis producing an average annual return of 29.58%. Currently, Novo Nordisk has a market capitalization of $208.88 billion. Buying $100 In NVO: If an investor had bought $100 of NVO stock 15 years ago, it would be worth $4,873.71 today based on a price of $47.12 for NVO at the time of writing. Novo Nordisk's Performance Over Last 15 Years Finally -- what's the point of all this? The key insight

First-quarter results indicated they have the momentum to do it.

The worst might be in the rearview mirror.